Blockchain Registration Transaction Record

Soligenix Advances Psoriasis Treatment in $67B Market Opportunity

Soligenix advances SGX302 phase 2a trial for psoriasis treatment, building on promising data in the $67B dermatology market. Company expands hypericin therapy pipeline.

The development of SGX302 represents a significant advancement in psoriasis treatment, a chronic autoimmune condition affecting approximately 125 million people worldwide who often struggle with limited treatment options and side effects from existing therapies. If successful, this synthetic hypericin therapy could provide a novel, well-tolerated alternative that addresses the substantial unmet medical need in dermatological care. For investors, Soligenix's progress in multiple therapeutic areas demonstrates the company's potential to capture value across both specialized biotherapeutics and public health markets, while patients stand to benefit from innovative treatments for conditions ranging from rare diseases to global health threats. The company's government-backed vaccine programs further highlight its strategic positioning in addressing critical public health needs.